Saluda Medical – BioScience Managers

Saluda Medical Receives FDA Approval for the Evoke® Spinal Cord Stimulation System to Treat Chronic Intractable Pain

16th March 2022/in BioSciences Managers, Saluda Medical, Uncategorised

Link to full article Artarmon, Australia – March 8, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced it received full approval from the United States Food and […]

Saluda Medical Announces $125M Equity Financing Led by Redmile Group LLC and New Investors Fidelity Management & Research Company LLC and T. Rowe Price Associates, Inc.

8th March 2022/in BioSciences Managers, Saluda Medical, Uncategorised

Link to full article March 2, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, earlier this quarter finalized US $125 million in equity financing, led by existing investor Redmile […]

Saluda Medical Appoints Doug Godshall as Chairman of the Board

8th March 2022/in BioSciences Managers, Saluda Medical, Uncategorised

Link to full article February 23, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced the appointment of Doug Godshall as Chairman of its […]

Publication of Two-Year EVOKE Double-Blind Randomized Controlled Trial Results in JAMA Neurology Demonstrate Sustained Superiority of Evoke® Closed-Loop over Open-Loop Spinal Cord Stimulation

8th March 2022/in BioSciences Managers, Closed Loop Medical, Saluda Medical, Uncategorised

Link to full article Study shows Evoke ECAP-Controlled Closed-Loop Spinal Cord Stimulation provides superior outcomes with no explants due to loss of efficacy and near zero reprogramming burden long term January 10, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global company on a mission to revolutionize the field of neuromodulation with an emerging portfolio […]

Saluda Medical Announces Publication of 24-Month Spinal Cord Stimulation Results with the Evoke® System

10th May 2021/in Saluda Medical

Link to Full Article Results show ~90% overall back and leg responder rate, ~68% high responder rate, and zero explants due to loss of efficacy ~83% of patients reduced or eliminated opioid use Need for patient re-programming visits nearly eliminated after 12 months Represents the first peer reviewed SCS study to show responder and high […]

Saluda Medical Announces Executive Leadership Changes

12th February 2021/in Saluda Medical

Link to Full Article Founder, CEO John Parker Taking on New Role as Chief Scientific Officer, Remaining on Board Artarmon, Australia – February 12, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann […]

Saluda Medical Announces Highlights from 2021 North American Neuromodulation Society (NANS) Meeting

20th January 2021/in Saluda Medical

Link to Full Article Artarmon, Australia – January 20, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights from the 2021 North American Neuromodulation Society (NANS 2021) Virtual Meeting, including real-world European commercial results and sub-analyses of 24-month […]

NICE Publishes Briefing on Saluda’s Evoke Closed-Loop Spinal Cord Stimulation (SCS) System

22nd December 2020/in Saluda Medical

Link to Full Article Artarmon, Australia – December 22, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) announced today that the UK’s National Institute for Health and Care Excellence (NICE) issued a Medtech Innovation Briefing (MIB) titled “Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain.” The MIB states Evoke would be used as a […]

Saluda Medical Appoints Jim Schuermann as President and Robert Gaffney as Chief Operating Officer

9th June 2020/in Saluda Medical

Link to Full Article Strengthens corporate leadership as company moves toward global commercialization Artarmon, Australia – June 9, 2020 – Saluda Medical Pty Limited (“Saluda Medical”), a global neuromodulation company leading the development and commercialization of data-driven, personalized therapies for patients with debilitating neurological disorders, today announced the key leadership appointments of Jim Schuermann as President and Robert Gaffney as Chief Operating […]

Saluda Medical Highlights Multiple Presentations Featuring Evoke® ECAP-Controlled, Closed-Loop SCS System at NANS Annual Meeting

24th January 2020/in Saluda Medical

Link to Full Article ARTARMON, NSW, Australia, January 21, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) today announced that data from multiple studies evaluating the company’s Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic pain will be featured in multiple presentations – including eight oral presentations and award of Best Clinical Abstract – during […]